GM
BBIO icon

GeoWealth Management’s BridgeBio Pharma BBIO Stock Holding History

GeoWealth Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,299
Closed -$482K – 859
2025
Q4 		$482K Sell
6,299
-12,922
-67% -$848K 0.02% 448
2025
Q3 		$998K Buy
+19,221
New +$937K 0.04% 299

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GeoWealth Management's BBIO Position: Q1 2026 in Review

GeoWealth Management sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 6,299 shares — an estimated $482K sold.

GeoWealth Management first reported a position in BBIO in Q3 2025 and held it in 2 quarters. The position peaked at $998K in Q3 2025. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • GeoWealth Management reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • GeoWealth Management sold 6,299 BridgeBio Pharma shares in Q1 2026, an estimated $482K.
  • GeoWealth Management first reported a position in BridgeBio Pharma in Q3 2025 and held it in 2 quarters.
  • GeoWealth Management's BridgeBio Pharma position peaked at $998K in Q3 2025.
  • 460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on GeoWealth Management's 13F filing for Q1 2026, filed 13 May 2026.